Ba/F3 cells and their use in kinase drug discovery
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Purpose of review Due to their ability to function as dominant oncogenes, protein kinases have become favored targets in the quest for 'molecularly-targeted' cancer chemotherapeutics. The discovery of a large number of cancer-associated mutations in the kinome, and the progress in developing specific small-molecule kinase inhibitors has increased the need for accurate, reproducible, and efficient kinase activity-dependent cellular assay systems. Recent findings Ba/F3, a murine interleukin-3 dependent pro-B cell line is increasingly popular as a model system for assessing both the potency and downstream signaling of kinase oncogenes, and the ability of small-molecule kinase inhibitors to block kinase activity. Facilitated by their growth properties, Ba/F3 cells have recently been adapted to high-throughput assay formats for compound profiling. Further, several published approaches show promise in predicting resistance to small-molecule kinase inhibitors elicited by point mutations interfering with inhibitor binding. Summary Ba/F3 cells are an increasingly popular tool in kinase drug discovery. The ability to test the transforming capacity of newly identified kinase mutations, and to profile drug candidates and compound libraries in high-throughput fashion, combined with the use of Ba/F3 cells to predict clinical resistance will greatly facilitate developments in this field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Palacios, R., & Steinmetz, M. (1985) · Cell · doi:10.1016/s0092-8674(85)80053-2 · Cited by 688
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB
Douma, S., van Laar, T., Zevenhoven, J., Meuwissen, R., van Garderen, E., & Peeper, D. S. (2004) · Nature · doi:10.1038/nature02765 · Cited by 607
Daley, G. Q., & Baltimore, D. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.23.9312 · Cited by 572
Management of malignant gastrointestinal stromal tumours
Joensuu, H., Fletcher, C., Dimitrijevic, S., Silberman, S., Roberts, P., & Demetri, G. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00899-9 · Cited by 567
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Kelly, L. M., Liu, Q., Kutok, J. L., Williams, I. R., Boulton, C. L., & Gilliland, D. G. (2002) · Blood · doi:10.1182/blood.v99.1.310 · Cited by 487
Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers
Bardelli, A., Parsons, D. W., Silliman, N., Ptak, J., Szabo, S., Saha, S., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., et al. (2003) · Science · doi:10.1126/science.1082596 · Cited by 484
Targeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 469
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393
Chen, L. L., Trent, J. C., Wu, E. F., Fuller, G. N., Ramdas, L., Zhang, W., Raymond, A. K., Prieto, V. G., Oyedeji, C. O., Hunt, K. K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0085 · Cited by 339
Stephens, P., Edkins, S., Davies, H., Greenman, C., Cox, C., Hunter, C., Bignell, G., Teague, J., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 332
Juxtamembrane autoinhibition in receptor tyrosine kinases
Hubbard, S. R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1399 · Cited by 325
Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.021 · Cited by 324
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., & Lodish, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509714102 · Cited by 316
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Bai, R.-Y., Dieter, P., Peschel, C., Morris, S. W., & Duyster, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.6951 · Cited by 281
Heidel, F., Solem, F. K., Breitenbuecher, F., Lipka, D. B., Kasper, S., Thiede, M. H., Brandts, C., Serve, H., Roesel, J., Giles, F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2469 · Cited by 270
Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R., & Gilliland, D. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14845 · Cited by 268
Ji, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B. L., McNamara, K., Xia, H., Glatt, K. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510284103 · Cited by 257
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 252
ETV6: A versatile player in leukemogenesis
Bohlander, S. K. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.01.008 · Cited by 204
An efficient rapid system for profiling the cellular activities of molecular libraries
Melnick, J. S., Janes, J., Kim, S., Chang, J. Y., Sipes, D. G., Gunderson, D., Jarnes, L., Matzen, J. T., Garcia, M. E., Hood, T. L., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511292103 · Cited by 186
Self-citationJiang, J., Greulich, H., Jänne, P. A., Sellers, W. R., Meyerson, M., & Griffin, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1829 · Cited by 186
Biology of chronic myelogenous leukemia—signaling pathways of initiation and transformation
Melo, J. V., & Deininger, M. W. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.03.008 · Cited by 166
von Bubnoff, N., Manley, P. W., Mestan, J., Sanger, J., Peschel, C., & Duyster, J. (2006) · Blood · doi:10.1182/blood-2005-12-010132 · Cited by 163
Cowan-Jacob, S., Guez, V., Fendrich, G., Griffin, J., Fabbro, D., Furet, P., Liebetanz, J., Mestan, J., & Manley, P. (2004) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557043487321 · Cited by 163
JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation
Staerk, J., Kallin, A., Demoulin, J.-B., Vainchenker, W., & Constantinescu, S. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500358200 · Cited by 163
Autoinhibition of Bcr-Abl through Its SH3 Domain
Smith, K. M., Yacobi, R., & Van Etten, R. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00274-0 · Cited by 162
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
Cortes, J. E., Ault, P. S., Koller, C. A., Thomas, D. M., Ferrajoli, A., Wierda, W. G., Rios, M. B., Letvak, L. A., Kaled, E. S., & Kantarjian, H. M. (2003) · Blood · doi:10.1182/blood-2003-01-0081 · Cited by 152
Shimamura, T., Ji, H., Minami, Y., Thomas, R. K., Lowell, A. M., Shah, K., Greulich, H., Glatt, K. A., Meyerson, M., Shapiro, G. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0971 · Cited by 134
de Menezes, D. E. L., Peng, J., Garrett, E. N., Louie, S. G., Lee, S. H., Wiesmann, M., Tang, Y., Shephard, L. B., Goldbeck, C., Oei, Y. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0358 · Cited by 114
Azam, M., Nardi, V., Shakespeare, W. C., Metcalf, C. A., Bohacek, R. S., Wang, Y., Sundaramoorthi, R., Piotr Sliz, A., Veach, D. R., Bornmann, W. G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600001103 · Cited by 112
Protein tyrosine kinases: autoregulation and small-molecule inhibition
Hubbard, S. R. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00383-4 · Cited by 91
FLT3 Tyrosine Kinase Inhibitors
Levis, M. J., & Small, D. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05079 · Cited by 78
Autoinhibitory mechanisms in receptor tyrosine kinases
Hubbard, S. R. (2002) · Frontiers in Bioscience · doi:10.2741/a778 · Cited by 50
Giles, F. J., Cortes, J. E., & Kantarjian, H. M. (2005) · Current Molecular Medicine · doi:10.2174/156652405774641115 · Cited by 34
von Bubnoff, N. C. C., Barwisch, S., Speicher, M. R., Peschel, C., & Duyster, J. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1560 · Cited by 32
Small Molecule FLT3 Tyrosine Kinase Inhibitors
Levis, M. J., & Small, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452604 · Cited by 27
KIT/Val654Ala Receptor Detected in One Imatinib-Resistant GIST Patient
Tamborini, E., Gabanti, E., Lagonigro, M. S., Negri, T., Pilotti, S., Pierotti, M. A., & Pricl, S. (2005) · Cancer Research · doi:10.1158/0008-5472.1115.65.3 · Cited by 22
A screen to identify drug resistant variants to target-directed anti-cancer agents
Azam, M., Raz, T., Nardi, V., Opitz, S. L., & Daley, G. Q. (2003) · Biological Procedures Online · doi:10.1251/bpo63 · Cited by 22
Small Molecule FLT3 Tyrosine Kinase Inhibitors
Levis, M. J., & Small, D. (2010) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/978160805206610603010399 · Cited by 6
Cited by
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01040 · Cited by 454
Self-citationIn vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Parmentier, J. M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H. S., Padley, R. J., George, J. S., Hyland, D., et al. (2018) · BMC Rheumatology · doi:10.1186/s41927-018-0031-x · Cited by 390
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
“…methods such as Western blots, phospho-ELISAs, reverse phase arrays, ALPHA (amplified luminescent proximity homogeneous assay)-screen assay and high content cellular analysis, and are being offered by various providers (Chen et al., 2005; Warmuth et al., 2007; Eglen et al., 2008; Jia et al., 2008).”
Method
Metadata
- Authors
- Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F.
- Affiliations
- Genomics Institute of the Novartis Research Foundation (US)
- Corresponding author
- Warmuth, Markus
- ORCID
- Xia, Gang
- Venue
- Current Opinion in Oncology
- Published
- 2007-01
- Volume
- 19
- Issue
- 1
- Pages
- 55-60
- ISSN
- 1040-8746 (ISSN-L)
- OpenAlex
- W2088757697
- Cited by
- 240
- References
- 60
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 27 · 2023: 22 · 2022: 25 · 2021: 19 · 2020: 18 · 2019: 5 · 2018: 13 · 2017: 14 · 2016: 14 · 2015: 9 · 2014: 11 · 2013: 10 · 2012: 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- Ba/F3 cells, protein kinases, kinase inhibitors, kinase drug discovery, oncogenes, small-molecule kinase inhibitors, high-throughput screening, compound profiling, drug resistance prediction, point mutations, downstream signaling, interleukin-3 dependence
- MeSH terms
- Animals, Antineoplastic Agents, Cell Line, Cell Transformation, Neoplastic, Epidermal Growth Factor, Drug Design, Signal Transduction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.